Brief: Kintor Pharmaceutical Says Investigational New Drug Application Of Gt90001's Phase Ii Clinical Trial For Advanced Hepatocellular (HCC) Approved By U.S. FDA
18/02/2021 05:17
Feb 18 (Reuters) - Kintor Pharmaceutical Ltd 9939.HK :
* INVESTIGATIONAL NEW DRUG APPLICATION OF GT90001'S PHASE II
CLINICAL TRIAL FOR ADVANCED HEPATOCELLULAR (HCC) APPROVED BY
U.S. FDA
Source text for Eikon: ID:nHKS6twh73
Further company coverage: 9939.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kintor Pharmaceutical
See all newsBrief: Kintor Pharmaceutical Receives Invention Patent Grant For KT-939 In China
Brief: Kintor Pharmaceutical Says Ming Ming Cheung Resigns As CFO
Brief: Kintor Pharmaceutical Says CEO Via Wholly Owned Co Increases Shareholding By 2.51 Million Shares
Brief: Kintor Pharmaceutical Says YTD 2026 Sales Revenue At RMB34 Million
Brief: Kintor Pharmaceutical Says Pharma's Kx-826 Phase Iii Trial In China Reaches Primary Endpoint